Investigational drug · Phase 3
Ebselen
Also called: SPI-1005
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Meniere's Disease, Ménière's Disease, Hearing Loss.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
16
Any phase or sponsor naming "Ebselen"
First trial start
2021
Oct 12, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ebselen", any sponsor or status.
- Phase 211
Conditions studied
As listed on its trial records.
- Meniere's Disease
- Ménière's Disease
- Hearing Loss
- Cochlear Trauma
- Covid19
- Corona Virus Infection
- Coronavirus
- Coronavirus Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Ebselen" as an intervention, largest first.
- SPI-1005 for the Treatment of Meniere's DiseasePivotal-lookingCompleted
Sound Pharmaceuticals, IncorporatedIndustry
NCT04677972 · 220 participants · Start Aug 2, 2022 · Primary completion Sep 19, 2023
Drug: Ebselen; Placebo · For: Meniere Disease; Ménière
Sites: Little Rock, Arkansas; Los Angeles, California; Roseville, California · 12 sites in all
- SPI-1005 for the Treatment of Meniere's Disease (Open Label)Pivotal-lookingActive, not recruiting
Sound Pharmaceuticals, IncorporatedIndustry
NCT06859788 · 200 participants (planned) · Start Oct 29, 2025 · Primary completion Dec 2026
Drug: Ebselen · For: Meniere's Disease; Ménière's Disease
Sites: Los Angeles, California; Boynton Beach, Florida; Delray Beach, Florida · 9 sites in all
- SPI-1005 for the Treatment of Patients With Meniere's DiseasePivotal-lookingCompleted
Sound Pharmaceuticals, IncorporatedIndustry
NCT03325790 · 149 participants · Start Sep 28, 2017 · Primary completion Apr 30, 2019
Drug: 200mg SPI-1005 BID; 400mg SPI-1005 BID · For: Meniere's Disease
Sites: Fresno, California; San Diego, California; San Francisco, California · 13 sites in all
Sound Pharmaceuticals, IncorporatedIndustry
NCT01444846 · 83 participants · Start Sep 2011 · Primary completion Dec 2013
Drug: SPI-1005 Low dose; SPI-1005 Middle dose and 2 more · For: Temporary Auditory Threshold Shift
Sites: Gainesville, Florida
- SPI-1005 Treatment in Moderate COVID-19 PatientsEnrolling by invitation
Sound Pharmaceuticals, IncorporatedIndustry
NCT04484025 · 60 participants (planned) · Start Oct 12, 2021 · Primary completion Dec 31, 2023
Drug: Ebselen; Placebo · For: Covid19; Corona Virus Infection; Coronavirus and 1 more
Sites: New Haven, Connecticut; Boise, Idaho; Kansas City, Kansas · 7 sites in all
- Signaling Mechanisms and Vascular Function in Patients With Diabetes MellitusPivotal-lookingCompleted
Brigham and Women's HospitalAcademic, hospital or other
NCT00762671 · 60 participants · Start May 1999 · Primary completion Oct 2007
Drug: Ebselen; Placebo · For: Type 1 Diabetes Mellitus; Type 2 Diabetes Mellitus
Sites: Boston, Massachusetts
University of OxfordAcademic, hospital or other
NCT03013400 · 60 participants · Start Oct 1, 2017 · Primary completion Jul 9, 2019
Drug: Ebselen; Placebo oral capsule · For: Bipolar Disorder; Bipolar Disorder, Manic
Sites: Oxford, United Kingdom
- IMPase in Treatment-resistant DepressionStatus unknown
University of OxfordAcademic, hospital or other
NCT05117710 · 50 participants (planned) · Start Apr 22, 2021 · Primary completion May 31, 2024
Drug: Ebselen; Placebo · For: Depressive Disorder, Treatment-Resistant
Sites: Oxford, United Kingdom
Sound Pharmaceuticals, IncorporatedIndustry
NCT06340633 · 40 participants (planned) · Start Dec 2026 · Primary completion Dec 2026
Drug: Ebselen; Placebo · For: Hearing Loss; Cochlear Trauma
Sites: Iowa City, Iowa; Columbus, Ohio; Philadelphia, Pennsylvania · 6 sites in all
Sound Pharmaceuticals, IncorporatedIndustry
NCT02603081 · 40 participants · Start Dec 2015 · Primary completion Aug 2017
Drug: SPI-1005 · For: Meniere's Disease
Sites: Los Angeles, California; New York, New York; Charleston, South Carolina · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Expression of concern "Ebselen attenuates oxidative DNA damage and enhances its repair activity in the thalamus after focal cortical infarction in hypertensive rats" [Brain Res. 1181 (2007) 83-92].
He M, Xing S, Yang B, et al. · Brain Res 2026
- Corrigendum to "Multifunctional Ebselen drug functions through the activation of DNA damage response and alterations in nuclear proteins" [Biochem. Pharmacol. 83(2) (2012) 296-303, https://doi.org/10.1016/j.bcp.2011.10.011].
Azad GK, Balkrishna SJ, Sathish N, et al. · Biochem Pharmacol 2026
- A novel ring-opened ebselen scaffold with potent anti-angiogenic activity against cancer: synthesis, biological evaluation, and molecular docking.
Feng S, Zhang Z, Zhong X, et al. · Bioorg Med Chem 2026
- Insights into the complexity of SARS-CoV-2 Mpro inhibition: Ebselen and its derivatives impair dimerisation of the enzyme.
Fabbian S, Fabi S, Schwarz L, et al. · J Enzyme Inhib Med Chem 2026
- Design, synthesis, antibacterial activity, and mechanistic studies of Ebselen derivatives against methicillin-resistant Staphylococcus aureus.
Chen Y, Wu XW, Liu SY, et al. · Bioorg Chem 2026
- Ebselen sensitizes multidrug-resistant cancer cells to doxorubicin by disrupting cellular redox homeostasis and inducing ferroptosis.
Baskar S, Anbiah SV, Prasad NR · Life Sci 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.